Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
84 Leser
Artikel bewerten:
(0)

Sinusitis Pipeline Market H1 2018 Therapeutic Analysis, Development and Drug Target

PUNE, India, April 5, 2018 /PRNewswire/ --

ReportsnReports.com adds the latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis Pipeline Market Review, H1 2018, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.

Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.

Complete research of Sinusitis Pipeline Market report including 87 pages with List of tables and list of figures available at http://www.reportsnreports.com/reports/1410920-sinusitis-pipeline-review-h1-2018.html

Pharmaceutical and Healthcare latest pipeline guide Sinusitis Pipeline Market Review, H1 2018, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sinusitis Pipeline Market (Ear Nose Throat Disorders) guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 4, 3 and 1 respectively.

Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Order a copy of Sinusitis Pipeline Review, H1 2018 report at http://www.reportsnreports.com/purchase.aspx?name=1410920

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sinusitis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sinusitis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders)

Related research titled '2015-2023 World Drugs for Sinusitis Market Research Report by Product Type, End-User / Application and Regions / Countries' has been prepared based on the synthesis, analysis, and interpretation of information about the global Drugs for Sinusitis market collected from specialized sources. The Drugs for Sinusitis market report covers key technological developments in the recent times and profiles leading players in the market are Sanofi, Bayer AG, Pfizer, AstraZeneca Plc, Novartis AG., Johnson & Johnson, Merck, Amgen, Bionorica SE, Dr. Reddy's Laboratories, Huasun and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Drugs for Sinusitis industry has been provided. Order a copy of this Drug for Sinusitis Market Research Report at http://www.reportsnreports.com/purchase.aspx?name=1260800 .

Explore more reports on the Pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.

Contact:
Hrishikesh Patwardhan
2nd Floor, Metropole,
Bund Garden Road,
Pune - 411001,India.
Tel: +1-888-391-5441
E-mail: sales@reportsandreports.com

Connect With Us on:

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds: http://www.reportsnreports.com/feed/p-181-prof-research.xml


© 2018 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.